Sueldos y Compensación en BenevolentAI

BenevolentAI is a London-based, clinical-stage HealthTech company founded in 2013 that applies advanced artificial intelligence and machine learning to accelerate drug discovery and development for complex diseases including cancer, neurology, and inflammation. Its proprietary AI platform — the Benevolent Platform — integrates and analyses vast scientific literature, biological data, and clinical evidence to generate novel drug-target hypotheses and guide drug design decisions with unprecedented speed and precision. Listed on Euronext Amsterdam and partnered with major pharmaceutical companies including AstraZeneca under deals worth up to $594 million, BenevolentAI is at the forefront of AI-driven pharmaceutical innovation in Europe.